ArticleBJUI compass2026
Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication-related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer. Methods: We retrospectively analysed 135 patients with prostate cancer and bone metastases who received bone-modifying agents (BMAs) between 2008 and 2025. Bone scintigraphy data were collected at baseline and during the BMA treatment. BSIJmax was calculated using computer-assisted diagnostic software (BONENAVI). Primary endpoints were BSIJmax in the maxilla and mandible before the clinical diagnosis of MRONJ, compared with baseline values. Secondary endpoints included area under the receiver operating characteristic curves (AUCs) for diagnosing MRONJ using BSIJmax in the maxilla and mandible. Results: Among 135 patients, 27 developed MRONJ during a median follow-up of 74 months (interquartile range, 41-124 months). Mandibular BSIJmax values before the clinical diagnosis of MRONJ were significantly higher than baseline values (0.090 vs. 0.027, Conclusion: The mandibular BSIJmax increased before the clinical diagnosis of MRONJ. The incorporation of BSIJmax into bone scintigraphy may enable early detection of MRONJ and timely intervention in patients with prostate cancer receiving BMA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.